-
公开(公告)号:US20230125234A1
公开(公告)日:2023-04-27
申请号:US17929032
申请日:2020-02-13
Applicant: UCB BIOPHARMA SRL
Inventor: David Alan COOK , Helen Margaret FINNEY , Stephen Edward RAPECKI
Abstract: The present disclosure relates to a bispecific anti CD44/anti CTLA4 antibody. The antibody construct has defined CDRs and variable chains sequences. The bispecific antibodies has improved activity on CDS and CD4 T cells compared to known antibodies.
-
公开(公告)号:US20230074381A1
公开(公告)日:2023-03-09
申请号:US17804934
申请日:2022-06-01
Applicant: UCB Biopharma SRL
Inventor: Helene Margaret Finney , Alastair David Griffiths Lawson , Stevan Graham Shaw , Bryan John Smith , Kerry Louise Tyson , Lara Kevorkian , Christoph Meier , Kaushik Sarkar , Paul Alan Atherfold
IPC: C07K16/28 , G01N33/50 , G01N33/564 , G01N33/68 , A61K47/60 , A61K47/64 , A61K39/395
Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
-
公开(公告)号:US20230070261A1
公开(公告)日:2023-03-09
申请号:US17759988
申请日:2021-02-01
Applicant: UCB BIOPHARMA SRL
Inventor: Neesha DEDI , Peter Charles ELLIOTT , Seppe Frans Roman LEYSEN , Sean MASON , David James MCMILLAN , Gillian Claire NESS , Niccolo PENGO , Martin Anthony REDHEAD , Alison TURNER , Kerry Louise TYSON
IPC: C07K16/40
Abstract: The present invention relates to antibodies which bind and inhibit KLK5 and methods of using the same to treat diseases caused by KLK5 imbalance. In particular, the present invention relates to inhibitory anti-KLK5 antibodies and their use in the treatment of Netherton disease, atopic dermatitis and cancer.
-
公开(公告)号:US11472794B2
公开(公告)日:2022-10-18
申请号:US16959339
申请日:2019-01-10
Applicant: UCB Biopharma SRL
Inventor: Gareth Neil Brace , Rose Elizabeth Bardell-Cox , Gregory Foulkes , James Richard Frost , Helen Tracey Horsley , Elizabeth Pearl Jones , Fabien Claude Lecomte , James Thomas Reuberson , Monika-Sarah Elizabeth Dorothea Schulze , Richard David Taylor , Wei Tsung Yau , Zhaoning Zhu
IPC: C07D403/12 , C07D413/12 , C07D407/14 , C07D235/16 , C07D401/14 , C07D413/14
Abstract: A series of substituted fused bicyclic imidazole derivatives, including benzimidazole derivatives and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
-
公开(公告)号:US20220235146A1
公开(公告)日:2022-07-28
申请号:US17541932
申请日:2021-12-03
Applicant: UCB BIOPHARMA SRL
Inventor: Ralph ADAMS , Thomas Allen CESKA , Anna Marie DAVIES , Alistair James HENRY , Xiaofeng LIU , James Michael MCDONNELL , Brian John SUTTON , Marta Katarzyna WESTWOOD
IPC: C07K16/42 , C07K16/28 , C07K14/735 , A61P37/08
Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the FcεRI receptor).
-
公开(公告)号:US20220222816A1
公开(公告)日:2022-07-14
申请号:US17607307
申请日:2020-04-28
Applicant: UCB Biopharma SRL
Inventor: Andrew Robert CARNELL , Joeri NICOLAES
Abstract: A machine-based learning system for predicting the presence of lesions indicative of axial spondyloarthritis in medical imaging data includes an image processor for receiving and processing one or more MRI image data set containing pelvic region and sacroiliac joint of a subject, and dividing said MRI image data set into a set of 3D voxels. The system also includes a voxel classifier for calculating for each of said the voxels one or more class probabilities of such voxel to contain a lesion of a particular type or being a non-lesion. The system also includes a lesion probability map generator for receiving the data produced by the voxel classifier and producing a probability intensity map for each of lesion types, in which one or more areas classified as lesion are highlighted; and an image display for displaying the output of the lesion probability map generator.
-
公开(公告)号:US20220211627A1
公开(公告)日:2022-07-07
申请号:US17595176
申请日:2020-05-13
Applicant: UCB BIOPHARMA SRL
IPC: A61K9/16 , A61K9/19 , A61K39/395
Abstract: The present invention is directed to pharmaceutical compositions, and in particular to slow release pharmaceutical compositions comprising antibody molecule-loaded polymeric microspheres, in the form of dry microparticles. The dry microparticles, and pharmaceutical compositions comprising said dry microparticles, are stable during manufacturing and upon storage and demonstrate interesting slow-release characteristics. In addition, the invention relates to methods for preparing said dry microparticles.
-
公开(公告)号:US11286266B2
公开(公告)日:2022-03-29
申请号:US17052978
申请日:2019-05-06
Applicant: UCB Biopharma SRL
Inventor: Hugues Chanteux , Yannick Quesnel , Claude Delatour , Laurent Provins
IPC: C07D513/04
Abstract: The present invention relates to 1-imidazothiadiazolo-2H-pyrrol-5-one derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
-
公开(公告)号:US20220073581A1
公开(公告)日:2022-03-10
申请号:US17259090
申请日:2019-07-10
Applicant: UCB BIOPHARMA SRL
Inventor: Ralph Adams , Terence Seward Baker , Xiaofeng Liu
IPC: C07K14/54 , C07K16/24 , C07K16/18 , C07K16/28 , C07K14/55 , C07K14/535 , C07K14/505
Abstract: The present invention provides antibodies comprising a variable (V) domain and an insert polypeptide, wherein the insert polypeptide is within the framework 3 region of the V domain.
-
公开(公告)号:US11155566B2
公开(公告)日:2021-10-26
申请号:US16771787
申请日:2018-12-04
Applicant: UCB Biopharma SRL
Inventor: Laurent Provins , Hugues Chanteux
IPC: C07D513/04
Abstract: The present invention relates to 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
-
-
-
-
-
-
-
-
-